ethyl 5-(thiophen-2-yl)-1H-pyrazole-4-carboxylate, 95.0%, 2g

(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine hemi((2S,3S)-2,3-bis((4-methylbenzoyl)oxy)succinate), 97%, 100mg

Trimethylphenylammonium Bromide>98.0%(HPLC)(T)25g

N-(thiophen-3-ylmethyl)methanesulfonamide, 98%, 1g

2-(Hydroxymethyl)isonicotinic acid, 97%, 100mg

Colonne HPLC NUCLEODUR® 300-5 C4 ec, 150 mm, 4 mm, 1 pièce(s)

N-Cyclohexyl-2-piperazin-1-yl-acetamide, 98.0%, 1g

Methyl o-tolylacetate, 98.0%, 10g

ETHYL 5-ETHYLOXAZOLE-4-CARBOXYLATE, 95.0%, 1g

(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)pentanoic acid, 97%, 250mg

Ethyl 4-methyl-2-{[4-(trifluoromethoxy)phenyl]amino}thiazole-5-carboxylate, 95.0%, 2g

9-(Bromomethyl)nonadecane>96.0%(GC)5mL

5-o-Tolyl-isoxazole-3-carboxylic acid methyl ester, 95.0%, 1g